title: Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy.
abstract: BACKGROUND
  Since the definition of different histologic subtypes of urothelial carcinomas by the World Health Organization (WHO) 2004 classification, description of molecular features and clinical behavior of these variants has gained more attention.
  
  
  METHODS
  We reviewed 205 tumor samples of patients with locally advanced bladder cancer mainly treated within the randomized AUO-AB05/95 trial with radical cystectomy and adjuvant cisplatin-based chemotherapy for histologic subtypes. 178 UC, 18 plasmacytoid (PUC) and 9 micropapillary (MPC) carcinomas of the bladder were identified. Kaplan Meier analysis and backward multivariate Cox's proportional hazards regression analysis were performed to compare overall survival between the three histologic subtypes.
  
  
  RESULTS
  Patients suffering from PUC have the worst clinical outcome regarding overall survival compared to conventional UC and MPC of the bladder that in turn seem have to best clinical outcome (27.4 months, 62.6 months, and 64.2 months, respectively; p=0.013 by Kaplan Meier analysis). Backward multivariate Cox´s proportional hazards regression analysis (adjusted to relevant clinicopathological parameters) showed a hazard ratio of 3.2 (p=0.045) for PUC in contrast to patients suffering from MPC.
  
  
  CONCLUSIONS
  Histopathological diagnosis of rare variants of urothelial carcinoma can identify patients with poor prognosis.
authors: Department of Urology, University Erlangen, Krankenhausstraße 12, Erlangen, 91054, Germany. bastian.keck@uk-erlangen.de
authors: Bastian
authors: B
authors: Keck
authors: Sven
authors: S
authors: Wach
authors: Robert
authors: R
authors: Stoehr
authors: Frank
authors: F
authors: Kunath
authors: Simone
authors: S
authors: Bertz
authors: Jan
authors: J
authors: Lehmann
authors: Michael
authors: M
authors: Stöckle
authors: Helge
authors: H
authors: Taubert
authors: Bernd
authors: B
authors: Wullich
authors: Arndt
authors: A
authors: Hartmann
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015653:Cystectomy / Q000009:adverse effects / Q000401:mortality; D005260:Female; D005858:Germany; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D019459:Urothelium / Q000187:drug effects* / Q000473:pathology / Q000601:surgery*
chemical_list: D002945:Cisplatin
references: Int J Cancer. 2011 Jul 15;129(2):346-54
references: 20878954
references: Mod Pathol. 2011 Aug;24(8):1111-9
references: 21516078
references: Urology. 2011 Apr;77(4):867-70
references: 21296399
references: Eur J Cancer. 2010 Mar;46(4):765-81
references: 20116997
references: Eur Urol. 2011 Jun;59(6):1009-18
references: 21454009
references: Am J Surg Pathol. 2009 Jul;33(7):1037-41
references: 19238079
references: BMC Urol. 2009 Jun 17;9:5
references: 19534791
references: Int J Urol. 2011 Jan;18(1):49-54
references: 21114685
references: Mod Pathol. 2011 May;24(5):729-38
references: 21336262
references: Urol Int. 2009;83(3):300-5
references: 19829030
references: Clin Cancer Res. 2010 Dec 1;16(23):5654-63
references: 21138866
references: Am J Surg Pathol. 2010 Sep;34(9):1367-76
references: 20717002
references: Cancer. 2007 Jul 1;110(1):62-7
references: 17542024
references: Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
references: 15939524
references: Rare Tumors. 2011 Apr 4;3(2):e22
references: 21769321
references: Am J Surg Pathol. 1994 Dec;18(12):1224-32
references: 7977945
references: Hum Pathol. 2010 Aug;41(8):1159-64
references: 20381120
references: Cancer Metastasis Rev. 2009 Dec;28(3-4):335-44
references: 20012924
references: Mod Pathol. 1993 Nov;6(6):660-2
references: 8302807
references: Urologe A. 2011 Feb;50(2):217-20
references: 21246348
references: J Clin Oncol. 2005 Aug 1;23(22):4963-74
references: 15939920
references: Int J Clin Oncol. 2011 Dec;16(6):759-62
references: 21732230
references: Eur Urol. 2005 Aug;48(2):189-199; discussion 199-201
references: 15939530
references: Pathology. 2010 Dec;42(7):650-4
references: 21080874